Protocol summary

Study aim
Study of the synergistic effects of grape seed extract with deferasirox on oxidative stress, hemoglobin levels, blood coagulation, serum ferritin levels and inflammatory biomarkers in children with major thalassemia
Design
A randomized, blinded, controlled clinical trial of 60 patients, enrolled between August 2020 and March 2021, and followed for 2 months
Settings and conduct
A randomized, blinded controlled clinical trial of 60 children with thalassemia major who meets inclusion criteria without any of the exclusion criteria are enrolled in the study. The study is performed in hematology and oncology Specialty and sub-specialty shahid Baghaee 2 hospital. Patients are randomly stratified into 2 groups. The first group receives deferasirox 30 mg/Kg PO daily and the second group receives deferasirox 30 mg/Kg PO daily plus grape seed extract 100 mg PO daily. patients and major researcher are blinded via simulation of drug and placebo packages. Data is collected at the start of the study, after 2 weeks and 4 weeks of treatment.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients affected by major thalassemia; Iron chelators consumption for at least 2 years; A history of iron chelators steady dose for the last 3 months; Having serum ferritin level more than 1000 μg/L Exclusion criteria: Change in iron chelator therapy during the study (6 months)
Intervention groups
Control group receives deferasirox 30mg /Kg daily PO. Case group receives deferasirox 30 mg/Kg daily plus grape seed extract 100 mg daily PO.
Main outcome variables
Glutathione peroxidase, superoxide dismutase, malondialdehyde, Glutathione, Hemoglobin, red blood cell count, prothrombin time, partial thromboplastin time,international normalized ratio, Billirubin direct and indirect, aminotransferase enzymes, alkaline phosphatase, Ferritin level, catalase enzyme activity, tissue necrosis factor-α, serum Albumin

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20180603039959N2
Registration date: 2020-10-05, 1399/07/14
Registration timing: registered_while_recruiting

Last update: 2020-10-05, 1399/07/14
Update count: 0
Registration date
2020-10-05, 1399/07/14
Registrant information
Name
bijan keikhaei
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 61 3375 0410
Email address
keikhaeib@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-08-22, 1399/06/01
Expected recruitment end date
2021-03-19, 1399/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Study of the synergistic effects of grape seed extract with deferasirox on oxidative stress, hemoglobin levels, blood coagulation, serum ferritin levels and inflammatory biomarkers in children with major thalassemia
Public title
Effects of grape seed extract on thalassemia major
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Patients affected by major thalassemia Iron chelators consumption for at least 2 years A history of iron chelator steady dose for the last 3 months Having serum ferritin level more than 1000 μg/L Patients with age limitation of 2 to 18 years old
Exclusion criteria:
Change in iron chelator therapy during the study (6 months)
Age
From 2 years old to 18 years old
Gender
Both
Phase
2
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization is simple. Randomization unit is individual. Randomization tool is sealed envelope. Concealment is performed through similar capsules containing drug and placebo. Random sequence generation is made by envelops shuffling.
Blinding (investigator's opinion)
Double blinded
Blinding description
In this double blind study, participants and the major researcher are kept blind to the study groups. Randomization tool is sealed envelope so that the major researcher is unaware of the envelope content delivered to the patients. Concealment is performed through similar capsules containing drug and placebo so that the participants are unaware of the prescribed drug .
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Ahvaz Jundishapur University of Medical Sciences
Street address
Golestan Ave., Shahid Baghaee sq., Shahid Baghaee 2 hospital.
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Approval date
2020-06-29, 1399/04/09
Ethics committee reference number
IR.AJUMS.REC.1399.307

Health conditions studied

1

Description of health condition studied
Thalassemia major
ICD-10 code
D56.1
ICD-10 code description
Beta thalassemia

Primary outcomes

1

Description
Glutathion peroxidase enzyme activity
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
For measurement of glutathion peroxidase enzyme activity ZellBio kits are used.

2

Description
Superoxide dismutase enzyme activity
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
For measurement of Superoxide dismutase enzyme activity ZellBio kits are used.

3

Description
Catalase enzyme activity
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
For measurement of Catalase enzyme activity ZellBio kits are used.

4

Description
TNF-alpha level
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
For measurement of TNF-alpha level IBL kit is used.

5

Description
Malon dyaldehyde level
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
For measurement of malon dyaldehyde the Satho method is used.

6

Description
Hemoglobin level
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Hemoglobin level is measured by Complete blood count test.

7

Description
Red blood cell count
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Red blood cell count is measured by Complete blood count test.

8

Description
Serum ferritin level
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Serum ferritin level is measured by serum ferritin level.

9

Description
Serum aminotransferase
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Serum aminotransferase is measured by aspartate aminotransferase (AST) test and alanine aminotransferase (ALT) test.

10

Description
Blood urea nitrogen level
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Serum blood urea nitrogen level is measured by Blood urea nitrogen (BUN) test.

11

Description
Serum creatinine
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Serum creatinine level is measured by creatinine test.

12

Description
Prothrombin time
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Prothrombin time is measured by Prothrombin time (PT) test.

13

Description
Partial thromboplastin time
Timepoint
At the beginning of the study, after 2 weeks of treatment, after 4 weeks of treatment.
Method of measurement
Partial thromboplastin time is measured by Partial thromboplastin time (PTT) test.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Patients are treated for 4 weeks with grape seed extract (made in Shari Pharmaceutical Industrial Company) 100 mg PO daily in combination with Deferasirox (made in Exir Pharmaceutical Industrial Company) 30 mg/Kg PO daily.
Category
Treatment - Other

2

Description
Control group: Patients are treated for 4 weeks with Deferasirox (made in Exir Pharmaceutical Industrial Company) 30 mg/Kg PO daily.
Category
Treatment - Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Shahid Baghaee 2 hospital
Full name of responsible person
Bijan Keikhaei dehdezi
Street address
Golestan Ave., Shahid Baghaee sq., Shahid Bagjhee 2 hospitl.2
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Phone
+98 61 3375 0411
Email
keikhaeib@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Bijan Keikhaei dehdezi
Street address
Golestan Ave., Shahid Baghaee sq., Shahid Baghaee 2 hospital.
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Phone
+98 61 3375 0411
Email
keikhaeib@yahoo.com
Grant name
Vice Chancellor for Research, Ahvaz University of Medical Sciences
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ahvaz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Bijan Keikhaei dehdezi
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Medical Education
Street address
golestan Ave,. Shahid Baghaee sq., Shahid Baghaee 2 hospital
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Phone
00980166173271
Email
keikhaeib@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Bijan Keikhaei dehdezi
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Medical Education
Street address
Golestan Ave., Shahid Baghaee sq., Shahid baghaee 2 hospital
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Phone
+98 916 617 3271
Email
keikhaeib@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Bijan Keikhaei dehdezi
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Medical Education
Street address
Golestan Ave., Shahid baghaee sq., Shahid Baghaee 2 hospital
City
Ahvaz
Province
Khouzestan
Postal code
6138933333
Phone
+98 916 617 3271
Email
keikhaeib@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Loading...